Oncology Testing: Algorithmic Assays 2025.2

Ovarian Cancer Treatment Algorithmic Tests

- I. Ovarian cancer treatment algorithmic tests are considered **medically necessary** when:
 - A. The member has a diagnosis of ovarian cancer, AND
 - B. The member is being considered for PARP inhibitor therapy.
- II. Ovarian cancer treatment algorithmic tests are considered **investigational** for all other indications.

REFERENCES

- 1. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 3.2024. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf
- Tew WP, Lacchetti C, Ellis A, et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J Clin Oncol. 2020;38(30):3468-3493. doi:10.1200/JCO.20.01924

